228 related articles for article (PubMed ID: 29517554)
1. Effectiveness and Drug Survival of Anti-Tumor Necrosis Factor α Therapies in Patients With Spondyloarthritis: Analysis From the Thai Rheumatic Disease Prior Authorization Registry.
Chiowchanwisawakit P; Katchamart W; Osiri M; Narongroeknawin P; Chevaisrakul P; Kitumnuaypong T; Siripaitoon B; Louthrenoo W
J Clin Rheumatol; 2019 Jan; 25(1):9-15. PubMed ID: 29517554
[TBL] [Abstract][Full Text] [Related]
2. Comparative Analysis and Predictors of 10-year Tumor Necrosis Factor Inhibitors Drug Survival in Patients with Spondyloarthritis: First-year Response Predicts Longterm Drug Persistence.
Flouri ID; Markatseli TE; Boki KA; Papadopoulos I; Skopouli FN; Voulgari PV; Settas L; Zisopoulos D; Iliopoulos A; Geborek P; Drosos AA; Boumpas DT; Sidiropoulos P
J Rheumatol; 2018 Jun; 45(6):785-794. PubMed ID: 29606666
[TBL] [Abstract][Full Text] [Related]
3. Eight-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Spondyloarthritis: A Multicenter Retrospective Analysis.
Favalli EG; Selmi C; Becciolini A; Biggioggero M; Ariani A; Santilli D; Fusaro E; Parisi S; Massarotti M; Marchesoni A; Meroni PL
Arthritis Care Res (Hoboken); 2017 Jun; 69(6):867-874. PubMed ID: 27696735
[TBL] [Abstract][Full Text] [Related]
4. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
[TBL] [Abstract][Full Text] [Related]
5. The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial Spondyloarthritis.
Nissen MJ; Ciurea A; Bernhard J; Tamborrini G; Mueller R; Weiss B; Toniolo M; Exer P; Gabay C; Finckh A;
Arthritis Rheumatol; 2016 Sep; 68(9):2141-50. PubMed ID: 27015429
[TBL] [Abstract][Full Text] [Related]
6. Effect of Comedication With Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Retention of Tumor Necrosis Factor Inhibitors in Patients With Spondyloarthritis: A Prospective Cohort Study.
Sepriano A; Ramiro S; van der Heijde D; Ávila-Ribeiro P; Fonseca R; Borges J; Teixeira L; Carvalho PD; Cerqueira M; Neves J; Meirinhos T; Barcelos A; Sequeira G; Salvador MJ; Canas da Silva J; Santos H; Bernardes M; Vieira-Sousa E; Canhão H; Branco JC; Pimentel-Santos F; Landewé R
Arthritis Rheumatol; 2016 Nov; 68(11):2671-2679. PubMed ID: 27273894
[TBL] [Abstract][Full Text] [Related]
7. Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey.
Lopalco G; Venerito V; Cantarini L; Emmi G; Salaffi F; Di Carlo M; Tafuri S; Gentileschi S; Di Scala G; Nivuori M; Cacciapaglia F; Galeazzi M; Lapadula G; Iannone F
Clin Exp Rheumatol; 2019; 37(5):762-767. PubMed ID: 31025925
[TBL] [Abstract][Full Text] [Related]
8. The effect of extra-articular manifestations on tumor necrosis factor-α inhibitor treatment duration in patients with ankylosing spondylitis: nationwide data from the Korean College of Rheumatology BIOlogics (KOBIO) registry.
Kim Y; Park S; Kim HS
Clin Rheumatol; 2018 Dec; 37(12):3275-3284. PubMed ID: 30251059
[TBL] [Abstract][Full Text] [Related]
9. Real-world Longterm Effectiveness of Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis Patients from the Rheumatic Diseases Portuguese Register.
Vieira-Sousa E; Eusébio M; Ávila-Ribeiro P; Khmelinskii N; Cruz-Machado R; Rocha TM; Bernardes M; Santos-Faria D; Silva JL; Santos H; Miguel C; Carvalho P; Costa T; Duarte AC; Meirinhos T; Nero P; Fonseca JE; Santos MJ
J Rheumatol; 2020 May; 47(5):690-700. PubMed ID: 31371659
[TBL] [Abstract][Full Text] [Related]
10. The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study.
Lie E; Kristensen LE; Forsblad-d'Elia H; Zverkova-Sandström T; Askling J; Jacobsson LT;
Ann Rheum Dis; 2015 Jun; 74(6):970-8. PubMed ID: 25710471
[TBL] [Abstract][Full Text] [Related]
11. Drug survival of tumor necrosis factor α inhibitors in patients with ankylosing spondylitis in Korea.
Jeong H; Eun YH; Kim IY; Kim H; Ahn JK; Lee J; Koh EM; Cha HS
Korean J Intern Med; 2018 Mar; 33(2):407-416. PubMed ID: 27729625
[TBL] [Abstract][Full Text] [Related]
12. Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers.
Hellgren K; Dreyer L; Arkema EV; Glintborg B; Jacobsson LT; Kristensen LE; Feltelius N; Hetland ML; Askling J;
Ann Rheum Dis; 2017 Jan; 76(1):105-111. PubMed ID: 27147709
[TBL] [Abstract][Full Text] [Related]
13. Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry.
Glintborg B; Sørensen IJ; Østergaard M; Dreyer L; Mohamoud AA; Krogh NS; Hendricks O; Andersen LS; Raun JL; Kowalski MR; Danielsen L; Pelck R; Nordin H; Pedersen JK; Kraus DG; Christensen SR; Hansen IM; Esbesen J; Schlemmer A; Loft AG; Al Chaer N; Salomonsen L; Hetland ML
J Rheumatol; 2017 Jan; 44(1):59-69. PubMed ID: 27909080
[TBL] [Abstract][Full Text] [Related]
14. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register.
Lie E; Lindström U; Zverkova-Sandström T; Olsen IC; Forsblad-d'Elia H; Askling J; Kapetanovic MC; Kristensen LE; Jacobsson LTH
Ann Rheum Dis; 2017 Sep; 76(9):1515-1521. PubMed ID: 28254789
[TBL] [Abstract][Full Text] [Related]
15. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.
Favalli EG; Pregnolato F; Biggioggero M; Becciolini A; Penatti AE; Marchesoni A; Meroni PL
Arthritis Care Res (Hoboken); 2016 Apr; 68(4):432-9. PubMed ID: 26556048
[TBL] [Abstract][Full Text] [Related]
16. Association between tobacco smoking and response to tumour necrosis factor α inhibitor treatment in psoriatic arthritis: results from the DANBIO registry.
Højgaard P; Glintborg B; Hetland ML; Hansen TH; Lage-Hansen PR; Petersen MH; Holland-Fischer M; Nilsson C; Loft AG; Andersen BN; Adelsten T; Jensen J; Omerovic E; Christensen R; Tarp U; Østgård R; Dreyer L
Ann Rheum Dis; 2015 Dec; 74(12):2130-6. PubMed ID: 25063827
[TBL] [Abstract][Full Text] [Related]
17. The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries.
Højgaard P; Glintborg B; Kristensen LE; Gudbjornsson B; Love TJ; Dreyer L
Rheumatology (Oxford); 2016 Dec; 55(12):2191-2199. PubMed ID: 27651526
[TBL] [Abstract][Full Text] [Related]
18. Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study.
Michielsens CAJ; den Broeder N; Mulder MLM; van den Hoogen FHJ; Verhoef LM; den Broeder AA
Rheumatology (Oxford); 2022 May; 61(6):2307-2315. PubMed ID: 34599803
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis.
Stober C; Ye W; Guruparan T; Htut E; Clunie G; Jadon D
Rheumatology (Oxford); 2018 Jan; 57(1):158-163. PubMed ID: 29077973
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor inhibitor (TNFi) persistence and reasons for discontinuation in a predominantly male cohort with axial spondyloarthritis.
Bekele DI; Cheng E; Reimold A; Geier C; Ganuthula K; Walsh JA; Clegg DO; Dubreuil M; Kaushik P; Ng B; Chang E; Duong R; Park J; Kerr GS
Rheumatol Int; 2022 Nov; 42(11):1925-1937. PubMed ID: 34724089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]